Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Dow
Boehringer Ingelheim
Johnson and Johnson
Colorcon

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for Vistusertib


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Vistusertib?

Vistusertib is an investigational drug.

There have been 14 clinical trials for Vistusertib. The most recent clinical trial was a Phase 2 trial, which was initiated on October 17th 2017.

The most common disease conditions in clinical trials are Lung Neoplasms, Lymphoma, B-Cell, and Lymphoma. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Samsung Medical Center.

There are one hundred and twenty-eight US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Vistusertib
TitleSponsorPhase
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)National Cancer Institute (NCI)Phase 1
Phase II Trial of Vistusertib´╝łAZD2014´╝ë Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard ChemotherapySamsung Medical CenterPhase 2
Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard ChemotherapySamsung Medical CenterPhase 2

See all Vistusertib clinical trials

Clinical Trial Summary for Vistusertib

Top disease conditions for Vistusertib
Top clinical trial sponsors for Vistusertib

See all Vistusertib clinical trials

US Patents for Vistusertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Vistusertib ⤷  Try it Free Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH) ⤷  Try it Free
Vistusertib ⤷  Try it Free Method for the diagnosis, prognosis and treatment of lung cancer metastasis Fundacio Institut de Recerca Biomedica (IRB Barcelona) (Barcelona, ES) Institucio Catalana de Recerca I Estudis Avancats (Barcelona, ES) ⤷  Try it Free
Vistusertib ⤷  Try it Free Benzimidazole derivatives as bromodomain inhibitors Gilead Sciences, Inc. (Foster City, CA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Dow
Boehringer Ingelheim
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.